Big Year For UCB As Bimzelx Awaits US Green Light
Psoriasis Approval Imminent After Delay
Executive Summary
The Brussels-based company's head of immunology has told Scrip that going into a crowded market against several highly effective biologics across different classes holds no fears for UCB despite some concerns that US prescribers will stick to what they know when it comes to psoriasis therapies.
You may also be interested in...
Wild Ride For Immunology? New Mechanisms, Big Indications Up For US FDA Approval In 2022
Major R&D efforts in immuno-dermatology produced multiple novel candidates in atopic dermatitis and psoriasis, while alopecia areata and vitiligo might see first therapies and JAK safety and COVID-19 logjams resolve.
UCB Jumps Early Onto M&A Merry-Go-Round With Zogenix Buy
Zogenix's Fintepla for Dravet syndrome got off to a slow start commercially and investors are hoping that the sales will improve considerably with UCB flexing its marketing muscles in the epilepsy space and growing the product as additional indications are secured.
A Deep Dive Into The Game-Changing Drugs For Skin Diseases
Scrip's Kevin Grogan joins Datamonitor's Pamela Spicer and Davinderpreet Mangat to discuss the skin disease landscape and whether atopic dermatitis is now where psoriasis was a decade ago as another wave of innovative products start to reach the market.